The Free Radical Cancer Biology Program (FRCBP) is unique to the HCCC and focuses on studying the biology of inherent differences in reductive and oxidative (redox) metabolism between cancer vs. normal cells. Research in the program is determining the role that redox reactions play in cancer phenotypic changes relevant to cell growth, differentiation, signal transduction, metastasis, functional molecular imaging, and therapy. A unifying goal of the program is to utilize a comprehensive basic science understanding of redox biology to develop novel biochemical rationales for improving cancer therapy. Three overlapping themes exist within the program. Theme 1: Understanding the role of redox biochemistry in regulation of genetic and epigenetic gene expression pathways relevant to cancer biology. Within this theme are research areas of focus exploring redox fluctuations and gene expression globally, as well as gene expression changes related of key redox sensitive molecules such as glutathione, thioredoxin, SOD, and AP2. Ttieme 2: Understanding the role of redox regulation in cell biology. Within this theme are research areas exploring the effects of redox on the cell cycle as well as invasion and metastasis. Ttieme 3: Exploring the role of oxidative stress in therapy outcomes. Within this theme are research areas exploring the role of manipulating oxidative stress to improve therapy as well as using imaging of oxidative metabolism as an approach to monitor and guide therapy. Major accomplishments of the FRCBP over the past funding period include findings that (a) cancer cells (relative to normal cells) produce increased steady-state levels of 02*'and H2O2 from mitochondrial metabolism that significantly contribute to differential susceptibility to clonogenic cell killing induced by glucose deprivation;(b) extracellular superoxide dismutase (EcSOD) inhibits invasion and metastasis;(c) expression of MnSOD governs the late production of reactive oxygen species, cell cycle check points, and transformation following radiation exposure;(d) that inhibitors of glucose and hydroperoxide metabolism can be used to enhance responses to radio-chemo-therapy by enhancing metabolic oxidative stress. The FRCBP consists of 18 members from 1 basic science department and 6 clinical departments and 2 colleges. Peer-reviewed, research funding for this program totals $3.9 million with over $2.0 million total costs from NCI. FRCBP members co-authored 237 publications. Of these publications, 20% were intraprogrammatic, 24% were interprogrammatic and 10% were both intra and interprogrammatic, for a total of 54% collaborative publications.

Public Health Relevance

It is becoming clear that metabolic oxidation/reduction reactions are altered in cancer vs. normal cells. The consensus is that cancer cells may exist in a chronic state of metabolic oxidative stress that may represent a significant underlying mechanism contributing to malignancy. A unifying goal of research in the FRCBP is to utilize a comprehensive understanding of cancer vs. normal cell redox biology to develop novel biochemical rationales for improving cancer therapy taking advantage fundamental differences in oxidative metabolism.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-12
Application #
8381307
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$44,646
Indirect Cost
$32,873
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Keck, Kendall J; Breheny, Patrick; Braun, Terry A et al. (2018) Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery 163:232-239
Schoenfeld, Joshua D; Sibenaller, Zita A; Mapuskar, Kranti A et al. (2018) Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models. Redox Biol 14:417-422
Kelpsch, Daniel J; Tootle, Tina L (2018) Nuclear Actin: From Discovery to Function. Anat Rec (Hoboken) 301:1999-2013
Gupta, Gaurav; Kuppachi, Sarat; Kalil, Roberto S et al. (2018) Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant 18:245-252
Garje, Rohan; Chau, Justin J; Chung, Jina et al. (2018) Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. J Immunother 41:42-44
Ruiz Ciancio, Dario; Vargas, Mauricio R; Thiel, William H et al. (2018) Aptamers as Diagnostic Tools in Cancer. Pharmaceuticals (Basel) 11:
Triplette, Matthew; Crothers, Kristina; Mahale, Parag et al. (2018) Risk of lung cancer in lung transplant recipients in the United States. Am J Transplant :
Andrew, Megan; Kim, Yusung; Ginader, Timothy et al. (2018) Reduction of applicator displacement in MR/CT-guided cervical cancer HDR brachytherapy by the use of patient hover transport system. J Contemp Brachytherapy 10:85-90
Buchakjian, Marisa R; Ginader, Timothy; Tasche, Kendall K et al. (2018) Independent Predictors of Prognosis Based on Oral Cavity Squamous Cell Carcinoma Surgical Margins. Otolaryngol Head Neck Surg 159:675-682
Brandt, Kristin E; Falls, Kelly C; Schoenfeld, Joshua D et al. (2018) Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells. Redox Biol 14:82-87

Showing the most recent 10 out of 1080 publications